Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-06-24
2010-06-08
Popa, Ileana (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S229100, C435S235100, C435S320100
Reexamination Certificate
active
07731952
ABSTRACT:
The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.
REFERENCES:
patent: 4769331 (1988-09-01), Roizman et al.
patent: 4859587 (1989-08-01), Roizman
patent: 5288641 (1994-02-01), Roizman
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5599691 (1997-02-01), Roizman
patent: 5728379 (1998-03-01), Martuza et al.
patent: 5824318 (1998-10-01), Mohr et al.
patent: 5846707 (1998-12-01), Roizman
patent: 5846948 (1998-12-01), Bruni et al.
patent: 5876923 (1999-03-01), Leopardi et al.
patent: 5922328 (1999-07-01), Spector et al.
patent: 6071692 (2000-06-01), Roizman
patent: 6120773 (2000-09-01), Roizman
patent: 6139834 (2000-10-01), Martuza et al.
patent: 6172047 (2001-01-01), Roizman et al.
patent: 6210926 (2001-04-01), Leopardi et al.
patent: 6218103 (2001-04-01), Leopardi et al.
patent: 6340673 (2002-01-01), Roizman et al.
patent: 6379674 (2002-04-01), Rabkin et al.
patent: 6383738 (2002-05-01), Bruni et al.
patent: 6537541 (2003-03-01), Breakefield et al.
patent: 6555108 (2003-04-01), Breakefield et al.
patent: 6610287 (2003-08-01), Breakefield et al.
patent: 6635416 (2003-10-01), Palese et al.
patent: 6699468 (2004-03-01), Martuza et al.
patent: 6723511 (2004-04-01), Leopardi et al.
patent: 6770274 (2004-08-01), Martuza et al.
patent: 6846670 (2005-01-01), Schwartz et al.
patent: 2002/0015944 (2002-02-01), Roizman et al.
patent: 2002/0019362 (2002-02-01), Weichselbaum et al.
patent: 2002/0127246 (2002-09-01), Rabkin et al.
patent: 2002/0155432 (2002-10-01), Schwartz et al.
patent: 2002/0187163 (2002-12-01), Johnson et al.
patent: 2002/0192822 (2002-12-01), Leopardi et al.
patent: 2003/0207829 (2003-11-01), Weichselbaum et al.
patent: 2004/0151697 (2004-08-01), Martuza et al.
patent: 2004/0228841 (2004-11-01), Martuza et al.
patent: 2005/0048491 (2005-03-01), Weichselbaum et al.
patent: 2005/0112142 (2005-05-01), Spaete et al.
patent: 2005/0232907 (2005-10-01), Rabkin et al.
Cassady et al., J Virol, 1998, 72: 8620-8626.
Coukos et al., Cancer Gene Therapy, 2000, 7: 275-283.
Skelly et al., Gene Therapy, 2001, 8: 1840-1846.
Huard et al., Neuromuscul. Disord., 1997, 7: 299-313, Abstract.
Lagunoff et al., J. Virol., 1995, 69: 3615-3623.
Markert et al., “Conditionally Replicating Herpes Simplex virus Mutant, G207 for the Treatment of Malignant Glioma: Results of a Phase I Trial,”Gene Ther. 7:867-874 (2000).
Mohr, I., “Genetic Metamorphosis of Herpes Simplex Virus-1 Into a Biological Therapeutic for Human Cancer,”Expert. Opin. Biol. Ther. 3(1):113-125 (2003).
“ICP47—HHV11/ICP47 Protein/US12 Protein,”UniProtKB/Swiss-Prot Entry P03170(Jul. 1, 1986).
Advani et al., “Replication-Competent, Nonneuroinvasive Genetically Engineered Herpes Virus is Highly Effective in the Treatment of Therapy-Resistant Experimental Human Tumors,”Cancer Res. 59:2055-2058 (1999).
Ahn et al., “Molecular Mechanism and Species Specificity of TAP Inhibition by Herpes Simplex Virus Protein ICP47,”EMBO J. 15:3247-3255 (1996).
Andreansky et al., “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,”Proc. Natl. Acad. Sci. USA93:11313-11318 (1996).
Basler et. al., “The Ebola Virus VP35 Protein Functions as a Type I IFN Antagonist,”Proc. Natl. Acad. Sci. USA97(22):12289-12294 (2000).
Beattie et al., “Reversal of the Interferon-Sensitive Phenotype of a Vaccinia Virus Lacking E3L by Expression of the Reovirus S4 Gene,”J. Virol. 69(1):499-505 (1995).
Bergmann et al., “Influenza Virus NS1 Protein Counteracts PKR-Mediated Inhibition of Replication,”J. Virol. 74(13):6203-6206 (2000).
Bolovan et al., “ICP34.5 Mutants of Herpes Simplex Virus Type 1 Strain 17syn+ Are Attenuated for Neurovirulence in Mice and for Replication in Confluent Primary Mouse Embryo Cell Cultures,”J. Virol. 68:48-55 (1994).
Boutell et al., “Herpes Simplex Virus Type 1 Immediate-Early Protein ICP0 and Its Isolated Ring Finger Domain Act As Ubiquitin E3 Ligases In vitro,”J. Virol. 76(2):841-850 (2002).
Bradley et al., “Ionizing Radiation Improves Survival in Mice Bearing Intracranial High-Grade Gliomas Injected With Genetically Modified Herpes Simplex Virus,”Clin. Cancer Res. 5:1517-1522 (1999).
Cassady et al., “Second-Site Mutation Outside of the Us10-12 Domain of Delta γI34.5 Herpes Simplex Virus 1 Recombinant Blocks the Shutoff of Protein Synthesis Induced by Activated Protein Kinase R and Partially Restores Neurovirulence,”J. Virol. 76:942-990 (2002).
Cassady & Gross, “The Herpes Simplex Virus Type 1 Us11 Protein Interacts With Protein Kinase R In Infected Cells and Requires a 30-Amino-Acid Sequence Adjacent to a Kinase Substrate Domain,”J. Virol. 76(5):2029-2035 (2002).
Chahlavi et al., “Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma,”Neoplasia1:162-169 (1999).
Chambers et al., “Comparison of Genetically Engineered Herpes Simplex Viruses for the Treatment of Brain Tumors in ascidMouse Model of Human Malignant Glioma,”Proc. Natl. Acad. Sci. USA92:1411-1415 (1995).
Chatterjee et al., “Effect of Cloned Human Interferons on Protein Synthesis and Morphogenesis of Herpes Simplex Virus,”J. Virol. 56(2):419-425 (1985).
Chee et al., “Promyelocytic Leukemia Protein Mediates Interferon-Based Anti-Herpes Simplex Virus 1 Effects,”J. Virol. 77(12):7101-7105 (2003).
Cheng et al., “Dephosphorylation of eIF2α Mediated By The γI34.5 Protein of Herpes Simplex Virus Type 1 is Required for Viral Response to Interferon but is not Sufficient for Efficient Viral Replication,”J. Virol. 77(18):10154-10161 (2003).
Child et al., “Complementation of Vaccinia Virus Lacking the Double-Stranded RNA-Binding Protein Gene E3L by Human Cytomegalovirus,”J. Virol. 76(10):4912-4918 (2002).
Chou et al., “Association of aMr90,000 Phosphoprotein With Protein Kinase PKR in Cells Exhibiting Enhanced Phosphorylation of Translation Initiation Factor eIF-2α and Premature Shutoff of Protein Synthesis After Infection With γI34.5−Mutants of Herpes Simplex Virus 1,”Proc. Natl. Acad. Sci. USA92:10516-10520 (1995).
Chou et al., “Mapping of Herpes Simplex Virus-1 Neurovirulence to γI34.5, a Gene Nonessential for Growth in Culture,”Science250:1262-1266 (1990).
Chou & Roizman, “The γI34.5 Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells From Triggering Total Shutoff of Protein Synthesis Characteristic of Programmed Cell Death in Neuronal Cells,”Proc. Natl. Acad. Sci. USA89:3266-3270 (1992).
Chung et al., “B-myb Promoter Retargeting of Herpes Simplex Virus γ34.5 Gene-Mediated Virulence Toward Tumor and Cycling Cells,”J. Virol. 73:7556-7564 (1999).
Coen et al., “Thymidine Kinase-Negative Herpes Simplex Virus Mutants Establish Latency in Mouse Trigeminal Ganglia But Do Not Reactivate,”Proc. Natl. Acad. Sci. USA86:4736-4740 (1989).
Davies et al., “The E3L and K3L Vaccinia Virus Gene Products Stimulate Translation Through Inhibition of the Double-Stranded R
Mohr Ian
Mulvey Matthew
Fish & Richardson P.C.
New York University
Popa Ileana
LandOfFree
Avirulent oncolytic herpes simplex virus strains engineered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avirulent oncolytic herpes simplex virus strains engineered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avirulent oncolytic herpes simplex virus strains engineered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200048